Late complications after treatment for Hodgkin lymphoma

Current Hematologic Malignancy Reports

Volumn 3, Issue 3, 2008, Pages 119-125

  Ng, Andrea K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; DRUG SUBSTITUTION; ENDOCRINE DISEASE; FEMALE STERILITY; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG CANCER; LUNG DISEASE; LUNG INSUFFICIENCY; NONHODGKIN LYMPHOMA; RADIATION DOSE; REVIEW; SECOND CANCER; SEPSIS; SOLID TUMOR; SPLENECTOMY; SURVIVAL TIME;

HEART DISEASES; HODGKIN DISEASE; HUMANS; HYPOTHYROIDISM; INFECTION; LEUKEMIA; LYMPHOMA, NON-HODGKIN; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; SURVIVORS;

EID: 47549094360     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0018-6     Document Type: Review

References (38)

1. Hoppe RT: Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997, 8:115-118.
2. Ng AK, Bernardo MP, Weller E, et al.: Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002, 20:2101-2108.
3. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al.: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003,21:3431-3439.
4. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al.: Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994, 12:1063-1073.
5. Kaldor JM, Day NE, Clarke EA, et al.: Leukemia following Hodgkin's disease. N Engl J Med 1990, 322:7-13.
6. Schonfeld SJ, Gilbert ES, Dores GM, et al.: Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst 2006, 98:215-218.
7. Ng AK, Bernardo MV, Weller E, et al.: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100:1989-1996.
8. Diehl V, Franklin J, Pfreundschuh M, et al.: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003, 348:2386-2395.
9. Rueffer U, Josting A, Franklin J, et al.: Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. J Clin Oncol 2001, 19:2026-2032.
10. Swerdlow AJ, Barber JA, Hudson GV, et al.: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000, 18:498-509.
11. van Leeuwen FE, Klokman WJ, Veer MB, et al.: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000, 18:487-497.
12. Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290:465-475.
13. van Leeuwen FE, Klokman WJ, Stovall M, et al.: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95:971-980.
14. Travis LB, Gospodarowicz M, Curtis RE, et al.: Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002, 94:182-192.
15. Girinsky T, van der Maazen R, Specht L, et al.: Involvednode radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79:270-277.
16. Hodgson DC, Koh ES, Tran TH, et al.: Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007, 110:2576-2586.
17. Swerdlow AJ, Schoemaker MJ, Allerton R, et al.: Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001, 19:1610-1618.
18. Heidenreich PA, Hancock SL, Lee BK, et al.: Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003, 42:743-749.
19. Hull MC, Morris CG, Pepine CJ, et al.: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003, 290:2831-2837.
20. Adams MJ, Lipsitz SR, Colan SD, et al.: Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004, 22:3139-3148.
21. Glanzmann C, Huguenin P, Lutolf UM, et al.: Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1994, 30:43-54.
22. Heidenreich PA, Hancock SL, Vagelos RH, et al.: Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005, 150:977-982.
23. Aviles A, Neri N, Nambo JM, et al.: Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 2005, 46:1023-1028.
24. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al.: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109:1878-1886.
25. Boivin JF, Hutchison GB, Lubin JH, et al.: Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992, 69:1241-1247.
26. Cosset JM, Henry-Amar M, Pellae-Cosset B, et al.: Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys 1991, 21:447-449.
27. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993, 270:1949-1955.
28. Swerdlow AJ, Higgins CD, Smith P, et al.: Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007, 99:206-214.
29. Heidenreich PA, Schnittger I, Strauss HW, et al.: Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007, 25:43-49.
30. Bowers DC, McNeil DE, Liu Y, et al.: Stroke as a late treatment effect of Hodgkin's disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005, 23:6508-6515.
31. Hirsch A, Vander Els N, Straus DJ, et al.: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.J Clin Oncol 1996, 14:1297-1305.
32. Martin WG, Ristow KM, Habermann TM, et al.: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005, 23:7614-7620.
33. Oldervoll LM, Kaasa S, Knobel H, et al.: Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors-results from a pilot study. Eur J Cancer 2003, 39:57-63.
34. Mauch P, Ng A, Aleman B, et al.: Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol 2005, 75:68-76.
35. De Bruin ML, Huisbrink J, Hauptmann M, et al.: Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008, 111:101-108.
36. Hodgson DC, Pintilie M, Gitterman L, et al.: Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007, 25:11-15.
37. Horning SJ, Hoppe RT, Breslin S, et al.: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630-637.
38. Sieniawski M, Reineke T, Nogova L, et al.: Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008, 111:71-76.